Yet, this inherent limitation also defines the unique value and immediate implication of our work: the ethnic homogeneity of our cohort provides a focused validation of KIF20A specifically within a Chinese patient population, which carries a substantial proportion of the global NSCLC burden. Here, KIF20A is linked to non-small cell lung carcinoma.